These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37224633)

  • 1. Structure-activity relationship of dihydropyridines for rhabdomyosarcoma.
    Chauhan S; Woods AD; Bharathy N; Lian X; Ricker CA; Mantz A; Zuercher WJ; Price LH; Morton MJ; Durrant E; Corbel SY; Sampath SC; Sampath SC; Joslin J; Keller C
    Biochem Biophys Res Commun; 2023 Jul; 667():138-145. PubMed ID: 37224633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
    Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
    Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 1,4-dihydropyridine derivatives with calcium channel blocking activity.
    Bladen C; Gündüz MG; Şimşek R; Şafak C; Zamponi GW
    Pflugers Arch; 2014 Jul; 466(7):1355-63. PubMed ID: 24149495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,4-Dihydropyridine: A Dependable Heterocyclic Ring with the Promising and the Most Anticipable Therapeutic Effects.
    Mishra AP; Bajpai A; Rai AK
    Mini Rev Med Chem; 2019; 19(15):1219-1254. PubMed ID: 31735158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): action in ion channels and GPCRs.
    Ioan P; Carosati E; Micucci M; Cruciani G; Broccatelli F; Zhorov BS; Chiarini A; Budriesi R
    Curr Med Chem; 2011; 18(32):4901-22. PubMed ID: 22050742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic screen for dihydropyridine (DHP)-resistant worms reveals new residues required for DHP-blockage of mammalian calcium channels.
    Kwok TC; Hui K; Kostelecki W; Ricker N; Selman G; Feng ZP; Roy PJ
    PLoS Genet; 2008 May; 4(5):e1000067. PubMed ID: 18464914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
    Ogihara T; Kano T; Kakinuma C
    Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular effects of calcium channel antagonists: new evidence.
    Richard S
    Drugs; 2005; 65 Suppl 2():1-10. PubMed ID: 16398057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
    Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
    Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.
    Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T
    Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities.
    Liang JC; Yeh JL; Wang CS; Liou SF; Tsai CH; Chen IJ
    Bioorg Med Chem; 2002 Mar; 10(3):719-30. PubMed ID: 11814861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential].
    Żorniak M; Mitręga K; Krzemiński TF
    Kardiol Pol; 2011; 69 Suppl 3():100-3. PubMed ID: 22125212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives.
    Takahashi D; Oyunzul L; Onoue S; Ito Y; Uchida S; Simsek R; Gunduz MG; Safak C; Yamada S
    Biol Pharm Bull; 2008 Mar; 31(3):473-9. PubMed ID: 18310913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.
    Paris D; Bachmeier C; Patel N; Quadros A; Volmar CH; Laporte V; Ganey J; Beaulieu-Abdelahad D; Ait-Ghezala G; Crawford F; Mullan MJ
    Mol Med; 2011; 17(3-4):149-62. PubMed ID: 21170472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.
    Bladen C; Gadotti VM; Gündüz MG; Berger ND; Şimşek R; Şafak C; Zamponi GW
    Pflugers Arch; 2015 Jun; 467(6):1237-47. PubMed ID: 24990197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 2-amino-1,4-dihydropyridine calcium antagonists. I. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having nitroxy-alkoxycarbonyl groups at 3- and/or 5-position.
    Kobayashi T; Inoue T; Kita Z; Yoshiya H; Nishino S; Oizumi K; Kimura T
    Chem Pharm Bull (Tokyo); 1995 May; 43(5):788-96. PubMed ID: 7553966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines.
    Bangalore R; Baindur N; Rutledge A; Triggle DJ; Kass RS
    Mol Pharmacol; 1994 Oct; 46(4):660-6. PubMed ID: 7969044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
    Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
    J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
    Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
    Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ATP-induced surfactant exocytosis by dihydropyridine (DHP) derivatives: a non-stereospecific, photoactivated effect and independent of L-type Ca2+ channels.
    Frick M; Siber G; Haller T; Mair N; Dietl P
    Biochem Pharmacol; 2001 May; 61(9):1161-7. PubMed ID: 11301050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.